Global Chronic Obstructive Pulmonary Disease Market   - Overview

The Chronic Obstructive Pulmonary Disease (COPD) Market size was valued at USD 1.82 billion in 2021 and is expected to expand from USD 3.07 billion in 2022 to USD 29.33 billion by 2030, with a compound yearly growth rate (CAGR) of 4.50% during the forecast period (2022 - 2030).

Chronic obstructive pulmonary disease (COPD) is a common disease among the geriatric population. Chronic obstructive pulmonary disease is a progressive lung disease characterised by erratic deteriorating of symptoms and these episodes are called acute exacerbations. Symptoms of COPD include increasing breathlessness, exhaustion, weight-loss, tightness in chest, panting, and others. Despite being curable and avoidable disease, the frequency continues to rise because of the universal prevalent of smoking. In the early stages, there may be no symptoms, but the symptoms gradually increase in later stages. The disease is related with huge healthcare costs. It has systemic effects, and common co-morbid conditions such as cardiovascular disease, muscle wasting, and osteoporosis may all be linked through a common systemic inflammatory cascade. Anxiety, malnutrition, depression, are also common in geriatric COPD patients. The two chief types of COPD are chronic bronchitis and emphysema. According to the American Lung Association (ALA), more than 10 million Americans above the age of 45 were suffering from chronic bronchitis in 2011. The risk of suffering from chronic bronchitis increases with age. Also, about 4.7 million Americans above the age of 45 were suffering from emphysema in 2011, according to the ALA.

Technological developments in chronic obstructive pulmonary disease area drives the market as they enable higher accuracy and cost-effectiveness. Factors such as growing frequencies of infectious diseases and various types of cancers increase in awareness, acceptance of personalized medicines are the factors expected to drive the market growth over the forecast period. Additionally, rise in occurrence rates of cardiovascular disorders, genetic disorders, neurological disorders are also expected to fuel the market growth.

The increase in funds by government and other organizations for clinical studies in healthcare sector is expected to increase the market growth. Regulatory ambiguities pertaining to approval process for novel medicines has always been the most critical restraining factor for the biotechnology, pharmaceutical, and medical technology market. The limited purchasing power of buyers in Africa and the absence of a healthy reimbursement framework for genomic and personalized medicine in established markets, such as the U.S., is likely to restrain the market growth. Additionally, in developing countries, such as China and India, lacks a well-defined regulatory framework and guidelines for the diagnostic sector, which negatively impacts the growth in this region irrespective of the presence of a large population.

Global Chronic Obstructive Pulmonary Disease Market   - Competitive Analysis

The Americas dominates the global chronic obstructive pulmonary disease market report due to increasing demand for the advanced techniques in pharmaceuticals, large elderly population, increase in the number of cases of infectious and chronic diseases, and acceptance of personalized medicines. Additionally, the advancement in technology and rise in government funds in research and development sector has fuelled the growth of the market in this region.

Abbott Laboratories is an American health care company headquartered in the U.S. Abbott Laboratories discovers, develops, produces, and sells health care products, worldwide. According to a press release published in November 2014, the study demonstrated that when elderly patients with chronic obstructive pulmonary disease market outlook received nutrition treatment or proper nourishment in the hospital, it reduced their length of stay by 1.88 days and total hospital costs by USD 1,570 on an average, in comparison to those who did not receive nutrition treatment. The study indicated the importance of proper nourishment from childhood.

Furthermore, AstraZeneca PLC, is an American health care company headquartered in the UK. It discovers, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, and infection diseases worldwide. Respiratory disease is one of AstraZeneca’s main therapy areas, and the company has a growing portfolio of medicines that reached more than 18 million patients in 2017. AstraZeneca’s purpose is to transform asthma and COPD treatment through inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification. VOYAGER is AstraZeneca’s Phase III Fasenra clinical trial programme in COPD and, with close to 4,000 patients, it is currently the largest COPD biologics development programme in the world. The VOYAGER programme includes two trials, GALATHEA and TERRANOVA, evaluating Fasenra in patients with moderate to very severe COPD with a history of exacerbations across a range of baseline blood eosinophils.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com